[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533585":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":23,"responsibleParty":50,"collaborators":7,"id":52,"slug":7,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":65,"studyType":66,"phases":7,"briefSummary":67,"conditions":68,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Gene Solutions","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Sinh D Nguyen","MGI","PRINCIPAL_INVESTIGATOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Lan NL Tu, PHD","CONTACT","+84888843489","lantu@genesolutions.vn",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"VAN T Phan, MSc","+84908145990","vanphan@genesolutions.vn",[24,39],{"facility":25,"status":26,"city":27,"state":28,"zip":7,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"University of Medicine and Pharmacy at HCMC","RECRUITING","Ho Chi Minh City","Hồ Chí Minh","Vietnam",{"type":31,"coordinates":32},"Point",[33,34],106.62965,10.82302,{"lat":34,"lon":33},[37],{"name":38,"role":16,"phone":7,"phoneExt":7,"email":7},"Vu T Le, PhD. MD",{"facility":40,"status":41,"city":27,"state":7,"zip":7,"country":29,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},"Medical Genetics Institute","NOT_YET_RECRUITING",{"type":31,"coordinates":43},[33,34],{"lat":34,"lon":33},[46,48],{"name":47,"role":16,"phone":17,"phoneExt":7,"email":18},"Lan NL Tu",{"name":49,"role":16,"phone":21,"phoneExt":7,"email":22},"VAN T Phan",{"type":51,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100533585",false,"NCT06227728","Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.","Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.","PTC-IMPACT","Inclusion Criteria:\n\n* 18 years and older, both genders.\n* Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.\n* FFPE\u002FFNA sample is available.\n* Compliant with treatment protocol.\n* Patients consented to participate in the study.\n\nExclusion Criteria:\n\n* Patients already started ICI before enrollment.\n* Consolidation ICI (eg. Durvalumab).\n* Patients already started chemotherapy before enrollment.\n* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.\n* Patients did not agree to participate in the studies.","ALL","18 Years","80 Years",{"count":63,"type":64},50,"ESTIMATED","3 Years","OBSERVATIONAL","This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.",[69,70,71,72,73,74,75],"Non Small Cell Lung Cancer","Breast Cancer","Colorectal Cancer","Gastric Cancer","Liver Cancer","Advanced Cancer","Immune Checkpoint Inhibitor","2026-01-14",{"date":78,"type":79},"2026-01-16","ACTUAL",{"date":81,"type":79},"2024-03-22",{"date":83,"type":64},"2026-12-31",{"name":5,"class":6},2]